Rizvan Bush

Subsequent malignant neoplasms among children with Hodgkin lymphoma: A report from the Children's Oncology Group.

K. Kelly, L. Constine, D. Friedman, 2020, Blood.

Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children's Oncology Group Study.

K. Kelly, S. Bhatia, D. Friedman, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.

K. Kelly, T. Horton, K. McCarten, 2018, The Lancet. Oncology.

Brentuximab vedotin with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma: A Children’s Oncology Group, Single-arm, Phase 1 / 2 Trial.

T. Horton, Q. Pei, R. Bush, 2019 .

Durable remission for four pediatric patients with high‐risk relapsed classical Hodgkin lymphoma treated with brentuximab vedotin plus gemcitabine but without autologous stem cell transplantation: A report from the Children's Oncology Group

K. Kelly, K. McCarten, M. Metzger, 2022, Pediatric blood & cancer.

Outcomes in intermediate‐risk pediatric lymphocyte‐predominant Hodgkin lymphoma: A report from the Children's Oncology Group

K. Kelly, D. Friedman, A. Buxton, 2018, Pediatric blood & cancer.